Patients receive pharmaceutical-grade peptides from vetted compounding pharmacies, detailed administration instructions, and ongoing monitoring to assess response and adjust protocols as needed

CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025
PubMed PMID 9920688 California Department of Alcoholic Beverage Control
Your HSA or FSA funds can also be used to cover monthly or yearly memberships at Iowa IV
It begins below the obesity-trial floor because appetite and gastrointestinal effects need time to adapt before escalation. At 5 mg, both GIP and GLP-1 are clinically active
Typical Daily Dosage and Frequency : The typical dosage is 250 mg to 500 mg per day, taken once or twice, depending on the individuals health needs